Valerian, a plant closely resembling Japanese valerian (Valeriana fauriei Briquet) has been listed in the Japanese pharmacopoeia (JP). n JP VIII (1971), the origin is stated as Valeriana officinalis Linne var latifolia Miquel. Valerian was listed in the 1926 United States pharmacopoeia (USP) and the 1932 British pharmacopoeia (BP). It was deleted from the USP and BP after that. However, Valerian was listed again in the BP in 1980 and in the USP twenty years after that in 2000. In this study, we discuss transitions of the standards and test methods of valerian described in the USP (2000-2011) and BP (1980-2011) and compare the USP and BP. The objective is to study to the pharmacological evaluation of valerian in USA and Britain. The standards and the test methods of valerianin early entries mainly described botanic characteristics together with macroscopic and microscopic features. However after valerian was listed again, the entries newly included identification tests, purity tests, standards and qualitative analysis of the components containing valerian used in mechanical analysis. This is based on the chemical properties and is a common feature in the USP and BP. There were some differences found in the items and the contents of the standards and the test methods of valerian when comparing the present USP and BP. It is thought that this reflects differences in the sense of values in pharmacy for the scientific aspects of valerian between USA and Britain. However, after Valerian was listed again, the standards and the test methods of valerian in the USP and BP included substantial information on chemical aspects. This sufficiently reflects the progress of the pharmacological level. Another factor is the increase in demand for valerian in the US and British markets in recent years. In addition, every time an amendment has been made to the USP and BP, the valerian drugs have increased. This is considered to be a necessary requirement for valerian to be listed again and to amend the standards and test methods of valerian in the USP and BP. As described above, valerian has been listed again in the USP and BP in recent years. A factor in this reevaluation of valerian is thought to be based on the increase in the demand in the markets of each country. t is necessary to examine the changes in the circulation of valerian in each country in recent years and investigate the reason that valerian was reevaluated in the market and the USP and BP.